Table 4.
HR (95% CI) of each endpoint with BMI by menopausal status among luminal B tumor
| BMI | Cases | Events | Recurrence | Events | Breast cancer–specific death | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||||
| Premenopausal | |||||||||
| ≥30 | 30 | 8 | 1.41 | 0.67–3.01 | 0.37 | 4 | 1.95 | 0.63–6.10 | 0.25 |
| ≥25–<30 | 114 | 17 | 0.97 | 0.57–1.66 | 0.91 | 7 | 1.07 | 0.45–2.55 | 0.87 |
| ≥21.8–<25 | 283 | 42 | 0.93 | 0.63–1.37 | 0.73 | 12 | 0.90 | 0.44–1.84 | 0.77 |
| ≥18.5–<21.8 | 481 | 73 | Reference | 23 | Reference | ||||
| <18.5 | 100 | 12 | 0.83 | 0.45–1.54 | 0.56 | 3 | 0.74 | 0.22–2.49 | 0.62 |
| P trend | 0.67 | 0.47 | |||||||
| Postmenopausal | |||||||||
| ≥30 | 109 | 18 | 1.09 | 0.66–1.80 | 0.72 | 14 | 3.24 | 1.71–6.17 | 0.0003 |
| ≥25–<30 | 613 | 76 | 0.81 | 0.61–1.09 | 0.16 | 29 | 1.19 | 0.71–1.99 | 0.5 |
| ≥21.8–<25 | 1054 | 147 | 1.02 | 0.80–1.30 | 0.89 | 46 | 1.27 | 0.80–2.02 | 0.31 |
| ≥18.5–<21.8 | 847 | 118 | Reference | 31 | Reference | ||||
| <18.5 | 215 | 27 | 0.95 | 0.63–1.45 | 0.81 | 10 | 1.39 | 0.68–2.86 | 0.37 |
| Ptrend | 0.35 | 0.022 | |||||||
HR, hazard ratio; CI, confidence interval; BMI, body mass index.
Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, and registered year.